Expanded Access to Cefiderocol for the Intravenous Treatment of Severe Gram Negative Bacterial Infections
Sponsor
Shionogi (Industry)
Overall Status
Approved for marketing
CT.gov ID
NCT03780140
Collaborator
(none)
Study Details
Study Description
Brief Summary
Expanded access may be provided for cefiderocol for qualified patients who have limited treatment options and are not eligible for a clinical trial.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
Study Design
Study Type:
Expanded Access
Official Title:
Expanded Access to Cefiderocol for the Intravenous Treatment of Severe Gram Negative Bacterial Infections
Outcome Measures
Primary Outcome Measures
Eligibility Criteria
Criteria
Ages Eligible for Study:
N/A
and Older
Sexes Eligible for Study:
All
Hospitalized patients with serious Gram-negative bacterial infections and who have limited treatment options and are not eligible for a clinical trial.
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Shionogi
Investigators
- Study Director: Shionogi Clinical Trials Administrator Clinical Support Help Line, Shionogi
Study Documents (Full-Text)
None provided.More Information
Additional Information:
Publications
None provided.Responsible Party:
Shionogi
ClinicalTrials.gov Identifier:
NCT03780140
Other Study ID Numbers:
- S-649266-EA
First Posted:
Dec 19, 2018
Last Update Posted:
Feb 28, 2020
Last Verified:
Feb 1, 2020
Keywords provided by Shionogi
Additional relevant MeSH terms: